Passer au contenu principal

Votre navigateur n’est malheureusement pas entièrement pris en charge. Si vous avez la possibilité de le faire, veuillez passer à une version plus récente ou utiliser Mozilla Firefox, Microsoft Edge, Google Chrome, ou Safari 14 ou plus récent. Si vous n’y parvenez pas et que vous avez besoin d’aide, veuillez nous faire part de vos commentaires.

Nous vous serions reconnaissants de nous faire part de vos commentaires sur cette nouvelle expérience.Faites-nous part de votre opinion

Elsevier
Publier avec nous

Profil

Anastasia Khvorova

Anastasia Khvorova

University of Massachusetts Chan Medical School, USA

Anastasia Khvorova, PhD, has more than two decades of experience pioneering oligonucleotide-based drug development. She began her scientific career in Moscow, where she completed her academic training and earned her doctorate in 1994. The following year, she moved to the United States, where she has conducted research at various universities and held senior positions in the pharmaceutical industry. She has co-founded several start-up companies.

Dr Khvorova has been a professor in the RNA Therapeutics Institute (RTI) and Program in Molecular Medicine at UMass Chan Medical School since 2012. She established the RTI Nucleic Acid Chemistry Center, which provides expertise in RNA chemistry to labs within and outside UMass Chan and is the only non-profit center in North America capable of synthesizing complex RNAs at scales necessary to support both in vitro and in vivo studies.

A prolific innovator, Anastasia holds more than 150 patents and is an elected fellow of National Academy of Inventors. She has authored more than 90 peer-reviewed publications, including seminal articles in Cell, Nature, and Nature Biotechnology (citation index exceeding 2000 per article) defining the field of RNAi drug design and development. Anastasia has served as director-at-large/scientific & research council chair of the American Society of Gene and Cell Therapy and currently is a director of the Oligonucleotide Therapeutics Society.